Highlights from the CHMP Feb 2026 Meeting are out! New Medicines 💊 Ipsen's tovorafenib (Ojemda; Type II RAF kinase inhibitor) is indicated as monotherapy for the treatment of patients 6 months of age and older with paediatric low‑grade glioma (LGG) harbouring a BRAF fusion or rearrangement, or BRAF V600 mutation, who have progressed after one or more prior systemic therapies New Biosimilars 💊 Henlius and Organon's pertuzumab (Poherdy; HER2/neu receptor antagonist), an inter